Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial

MT Newswires Live

Sep 06, 2024

China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.

Herpes zoster causes painful rashes or blisters on the skin.

The clinical trials will not have any major impact on the company's revenue, the filing said.

Shares slipped 2% during Friday's afternoon trading.

Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2465550346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2465550346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2465550346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-06 14:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465550346","market":"us","top_or_hot":-1,"title":"Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial","media":"MT Newswires Live","content":"<html><body><p> China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.</p><p>Herpes zoster causes painful rashes or blisters on the skin.</p><p>The clinical trials will not have any major impact on the company's revenue, the filing said.</p><p>Shares slipped 2% during Friday's afternoon trading.</p><p>Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-06 14:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.</p><p>Herpes zoster causes painful rashes or blisters on the skin.</p><p>The clinical trials will not have any major impact on the company's revenue, the filing said.</p><p>Shares slipped 2% during Friday's afternoon trading.</p><p>Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2465550346","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465550346","pubTimestamp":1725605299,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's medical products administrator granted Sinocelltech Group  subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.Herpes zoster causes painful rashes or blisters on the skin.The clinical trials will not have any major impact on the company's revenue, the filing said.Shares slipped 2% during Friday's afternoon trading.Price : 32.72, Change: -0.56, Percent Change: -1.68%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688520":"神州细胞","BK0239":"医药制造"},"translate_title":"Sinocelltech集团带状疱疹疫苗试验获得中国认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688520":0.9},"content_text":"China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.Herpes zoster causes painful rashes or blisters on the skin.The clinical trials will not have any major impact on the company's revenue, the filing said.Shares slipped 2% during Friday's afternoon trading.Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}